JP2017531699A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531699A5
JP2017531699A5 JP2017540976A JP2017540976A JP2017531699A5 JP 2017531699 A5 JP2017531699 A5 JP 2017531699A5 JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017540976 A JP2017540976 A JP 2017540976A JP 2017531699 A5 JP2017531699 A5 JP 2017531699A5
Authority
JP
Japan
Prior art keywords
dose
hpv
use according
vaccine
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017540976A
Other languages
English (en)
Japanese (ja)
Other versions
JP6663438B2 (ja
JP2017531699A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/057150 external-priority patent/WO2016065281A1/en
Publication of JP2017531699A publication Critical patent/JP2017531699A/ja
Publication of JP2017531699A5 publication Critical patent/JP2017531699A5/ja
Application granted granted Critical
Publication of JP6663438B2 publication Critical patent/JP6663438B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017540976A 2014-10-24 2015-10-23 癌および皮膚病変の治療 Active JP6663438B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068332P 2014-10-24 2014-10-24
US62/068,332 2014-10-24
PCT/US2015/057150 WO2016065281A1 (en) 2014-10-24 2015-10-23 Cancer and skin lesion treatment

Publications (3)

Publication Number Publication Date
JP2017531699A JP2017531699A (ja) 2017-10-26
JP2017531699A5 true JP2017531699A5 (OSRAM) 2018-11-15
JP6663438B2 JP6663438B2 (ja) 2020-03-11

Family

ID=55761638

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017540976A Active JP6663438B2 (ja) 2014-10-24 2015-10-23 癌および皮膚病変の治療

Country Status (15)

Country Link
US (1) US10238729B2 (OSRAM)
EP (1) EP3209676A4 (OSRAM)
JP (1) JP6663438B2 (OSRAM)
KR (1) KR102285401B1 (OSRAM)
CN (1) CN107001430A (OSRAM)
AU (1) AU2015335652B2 (OSRAM)
BR (1) BR112017008280A2 (OSRAM)
CA (1) CA2965498A1 (OSRAM)
CL (1) CL2017001008A1 (OSRAM)
IL (1) IL251825B2 (OSRAM)
MX (1) MX395186B (OSRAM)
MY (1) MY195018A (OSRAM)
PH (1) PH12017500754A1 (OSRAM)
SG (1) SG11201703262UA (OSRAM)
WO (1) WO2016065281A1 (OSRAM)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018067550A2 (pt) * 2016-02-27 2019-10-01 Hpvvax, Llc. métodos para tratar um paciente que tem câncer de pele, tumor benigno ou canceroso ou uma lesão associada a papilomavírus humano (hpv), e composição farmacêutica

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1243655B1 (en) * 2001-03-23 2007-02-21 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Modified HPV E6 and E7 genes and proteins useful for vaccination
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
US20060222656A1 (en) 2005-04-01 2006-10-05 University Of Maryland, Baltimore MAGE-A3/HPV 16 peptide vaccines for head and neck cancer
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0206359D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
WO2004056389A1 (en) 2002-12-20 2004-07-08 Glaxosmithkline Biologicals Sa Hpv-16 and -18 l1 vlp vaccine
RU2420313C2 (ru) * 2004-06-16 2011-06-10 ГлаксоСмитКлайн Байолоджикалз с.а. Вакцина против вирусов папилломы человека hpv 16 и hpv 18 и по меньшей мере еще одного типа hpv, выбранного из hpv 31, 45 или 52
US8399610B2 (en) 2004-08-05 2013-03-19 University College Cardiff Consultants Limited HPV vaccine comprising peptides from host cell proteins
GB0417430D0 (en) 2004-08-05 2004-09-08 Uc3 A novel HPV vaccine comprising peptides from host cell proteins
JP2010520874A (ja) * 2007-03-09 2010-06-17 メルク・シャープ・エンド・ドーム・コーポレイション パピローマウイルスワクチン組成物
CN101530612A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 16型重组人乳头瘤病毒疫苗
CN101530614A (zh) * 2008-03-10 2009-09-16 北京康乐卫士生物技术有限公司 五价重组人乳头瘤病毒疫苗
EP2271361A1 (en) 2008-04-16 2011-01-12 Université de Lausanne Method and vaccine for optimizing the specific immune responses
CN102458440A (zh) * 2009-04-10 2012-05-16 约翰·霍普金斯大学 作为广谱人类乳头状瘤病毒(hpv)疫苗的乳头状瘤病毒样颗粒(vlp)
ES2683352T3 (es) * 2009-04-13 2018-09-26 Inserm - Institut National De La Santé Et De La Recherche Médicale Partículas de HPV y usos de las mismas
CN101890160B (zh) * 2009-04-28 2014-06-18 北京康乐卫士生物技术有限公司 多价重组人乳头瘤病毒疫苗及其应用
CN102215861B (zh) 2009-06-19 2014-10-08 艾金株式会社 宫颈癌疫苗
KR20120098580A (ko) * 2009-06-25 2012-09-05 글락소스미스클라인 바이오로지칼즈 에스.에이. 인간 파필로마바이러스（ｈｐｖ） 단백질 작제물 및 ｈｐｖ 질환을 예방하기 위한 이의 용도
AR074485A1 (es) 2009-12-04 2011-01-19 Consejo Nac Invest Cient Tec Vacuna contra lesiones neoplasicas o cancerosas causadas por el virus del papiloma humano (vph), procedimientos, usos y metodos
EP2717884A1 (en) * 2011-06-06 2014-04-16 Chevron Phillips Chemical Company LP Use of metallocene compounds for cancer treatment
US20130064849A1 (en) * 2011-07-14 2013-03-14 The Board Of Regents Of The University Of Texas Methods to treat and prevent cardiovascular disease using human papillomavirus vaccines
BR112014023092A8 (pt) * 2012-03-18 2017-07-25 Glaxosmithkline Biologicals Sa Composição imunogênica, método para a prevenção de infecção ou doença por hpv em um indivíduo, e, kit
WO2013149017A1 (en) * 2012-03-28 2013-10-03 Kansas State University Research Foundation Vaccine adjuvant
US20140275082A1 (en) * 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2016538333A (ja) 2013-10-13 2016-12-08 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー ヒトパピローマウイルス治療ワクチン

Similar Documents

Publication Publication Date Title
ES2848064T3 (es) Vacuna terapéutica potenciadora de inmunidad para VPH y enfermedades relacionadas
Abeck et al. Quadrivalent human papillomavirus vaccination: a promising treatment for recalcitrant cutaneous warts in children
JP2015533376A5 (OSRAM)
JP2016537417A5 (OSRAM)
JP2010530362A5 (OSRAM)
Tran et al. Spontaneous regression of metastatic melanoma after inoculation with tetanus–diphtheria–pertussis vaccine
SA521421371B1 (ar) لقاحات الببتيد
Devaraja Current prospects of molecular therapeutics in head and neck squamous cell carcinoma
Suckow Cancer vaccines: harnessing the potential of anti-tumor immunity
Ding et al. Effectiveness of combination therapy with ISA101 vaccine for the treatment of human papillomavirus-induced cervical cancer
JP2018509423A5 (OSRAM)
JP7460094B2 (ja) 子宮頸がんの治療方法
CN119770632A (zh) 诱导免疫应答的组合物和方法
JP2017531699A5 (OSRAM)
JP6663438B2 (ja) 癌および皮膚病変の治療
Wang et al. The role and development of peptide vaccines in cervical cancer treatment
EP4196157A1 (en) Compositions for treating gastrointestinal adenocarcinomas by altering the tumor microenvironment
Granadillo et al. LALF32-51-E7 therapeutic vaccine induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the lungs
RU2832963C2 (ru) Способ лечения рака шейки матки
HK1241898A1 (en) Cancer and skin lesion treatment
Kumar et al. The Current Landscape for Human Papillomavirus Vaccination in Oropharyngeal Carcinoma
Draganov et al. 290 Cytokine and immune subset signatures in patients with various solid and hematological malignancies treated with oncolytic vaccinia virus delivered by autologous stromal vascular fraction cells
Melief Peptide-based therapeutic cancer vaccines
Alfonso et al. Biological activity of LALF32-51–E7, a vaccine candidate for the treatment of anogenital lesions associated to HPV16
Elliott Human Papillomavirus 9-valent Vaccine, Recombinant (Gardasil® 9)